Scope and Claims Analysis of US Patent 8,981,103: Crystal Forms of 6-(3-chloro-2-fluorobenzyl)-1-[(S)-1-hydroxymethyl-2-methylpropyl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (and Purity/Composition Claims)
US 8,981,103 is a crystal-form and solid-state IP patent built around (i) tightly defined XRPD peak sets for a specific substituted dihydroquinoline carboxylic acid scaffold, (ii) dependent claim narrowing through peak-count and peak-position tolerance windows, and (iii) downstream product protection via crystal purity thresholds and pharmaceutical compositions (including tablet/pill/powder/granule). The practical claim “center of gravity” is the XRPD peak pattern language at ~8.54° (± tolerance) and the inclusion of additional peaks at ~14.02° and ~17.24° (and in broader form claim sets at additional positions such as ~15.68/15.8, ~17.06, ~24.16, ~25.74).
Because the independent claim set is claim 1 (and claim 10) style crystal-characterization claims, enforceability and design-around risk track directly to whether a competitor’s solid matches the claimed XRPD peak positions within the recited ± degrees ranges, and whether their material has the required crystal purity level if they practice within claims 14–18. Composition claims (19–20) depend on using “the crystal form of any one of claims 1 and 2 to 13,” so composition protection is gated by infringement of the underlying solid-state claims.
What crystal-form claims are in US 8,981,103, and what exact XRPD peaks define infringement?
Short answer: The patent claims crystal forms of the specific drug substance by requiring XRPD “characteristic diffraction peaks” at specified 2θ positions with defined tolerance windows. Claim 1 targets a minimum one-peak requirement at ~8.54°; claim 10 targets a broader multi-peak fingerprint including peaks at ~8.54°, ~14.02°, ~15.8/15.68, ~17.06, ~17.24, ~24.16, and ~25.74; intermediate dependent claims add peaks stepwise.
Core active-ingredient scaffold in the claim preamble
All independent/base crystal claims recite:
- 6-(3-chloro-2-fluorobenzyl)-1-[(S)-1-hydroxymethyl-2-methylpropyl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
So the patent’s solid-state exclusivity is for this specific molecular entity; there is no claim shown here that covers salt forms, polymorphs of related analogs, or alternative substitution patterns.
Claim 1: single-peak crystal definition
- Crystal form with XRPD characteristic peak at 8.54 ± 0.2° (2θ)
This is the broadest shown XRPD embodiment because it only requires one peak meeting that criterion.
Claims 2–3: narrower tolerance on the same main peak
- Claim 2: 8.54 ± 0.1°
- Claim 3: 8.54 ± 0.06°
These are narrower in tolerance width, not peak position count.
Claims 4–9: stepwise addition of a second/third peak
- Claim 4: claim 1 plus additional peak at 17.24 ± 0.2°
- Claim 5: peaks 8.54 ± 0.1° and 17.24 ± 0.1°
- Claim 6: peaks 8.54 ± 0.06° and 17.24 ± 0.06°
- Claim 7: claim 4 plus additional peak at 14.02 ± 0.2°
- Claim 8: peaks 8.54 ± 0.1°, 14.02 ± 0.1°, 17.24 ± 0.1°
- Claim 9: peaks 8.54 ± 0.06°, 14.02 ± 0.06°, 17.24 ± 0.06°
This creates a tiered ladder: (1) main peak only, (2) main + one secondary peak, (3) main + two secondary peaks, with dependent claims tightening tolerances.
Claim 10: broader fingerprint with seven peak positions
- Requires a multi-peak XRPD set at 8.54, 14.02, 15.8, 17.06, 17.24, 24.16, 25.74, each within ±0.2° (shown).
Claims 11–12 provide narrower tolerance bands for the same multi-peak set:
- Claim 11: ±0.1° (and uses 15.68 ± 0.1° instead of 15.8 ±0.2° in the snippet you provided)
- Claim 12: ±0.06° (with the set as 15.68/17.06/… in the snippet language)
Implication for infringement testing: multi-peak claims increase evidentiary burden for a patentee (and also increase design-around opportunities) because a competitor must match the whole fingerprint within all tolerances simultaneously. Single-peak claims are easier to satisfy but increase validity/enforceability complexity in litigation, depending on how the specification defines “characteristic peaks” and how distinct the claimed form is from other solids.
Claim 13: “Crystal form III” as shown in FIG. 1
- “Crystal form III” having XRPD pattern “as shown in FIG. 1.”
This type of claim can anchor a court’s construction of what FIG. 1 corresponds to, but in enforcement it still typically collapses back to measurable XRPD peak criteria. Without the figure data, the practical scope is defined by how FIG. 1 maps to the peak positions recited in the other claims.
Which dependent claims narrow the XRPD peak set and how does that affect claim coverage?
Short answer: The dependent claims narrow by adding peaks (increasing required peak count) and tightening peak tolerances (reducing allowable drift in 2θ). In solid-state disputes, this directly changes the likelihood that a different manufacturing process or comminution/co-crystal contamination alters the measured peak positions enough to avoid infringement.
Peak-position tolerance ladder
- ±0.2° appears in the broadest versions.
- ±0.1° tightens.
- ±0.06° is the tightest shown band.
Peak-count ladder
- 1 peak: claim 1
- 2 peaks: claims 4–6 (8.54 + 17.24)
- 3 peaks: claims 7–9 (8.54 + 14.02 + 17.24)
- 7 peaks: claim 10 (and claims 11–12 with tighter tolerances)
Practical coverage consequences
- Claim 1 style (single peak): broader coverage, higher chance that multiple solids could share a coincident peak near 8.54°.
- Claim 10 style (7 peaks): narrower coverage, but stronger fingerprinting that can more reliably differentiate the claimed polymorph from close analogs.
What crystal purity claims (14–18) add a manufacturing-quality gate for infringement?
Short answer: Claims 14–18 impose minimum “purity of crystal” thresholds (70%, 80%, 90%, 95%, 98%) for the claimed crystal forms. Even if a competitor’s XRPD matches peak criteria, failing the purity threshold can avoid infringement of those purity-dependent claims.
Purity threshold ladder
- Claim 14: purity of crystal ≥70%
- Claim 15: ≥80%
- Claim 16: ≥90%
- Claim 17: ≥95%
- Claim 18: ≥98%
Scope effect
These claims protect against “mixed solids” where a competitor uses the same XRPD-identifiable polymorph but with lower crystalline purity due to residual amorphous material, intergrown forms, or polymorph admixture. They also create a second dimension for defense: measurement method and sampling plan for “purity of crystal” can be decisive.
What pharmaceutical composition claims are protected (and what dosage forms are explicitly covered)?
Short answer: Claims 19–20 protect pharmaceutical compositions that include the claimed crystal form plus a pharmaceutically acceptable carrier. Claim 20 specifies composition formats: tablet, pill, powder, or granule.
Claim 19: composition of claimed crystal form
- “A pharmaceutical composition comprising the crystal form of any one of claims 1 and 2 to 13 and a pharmaceutically acceptable carrier.”
Coverage is broad across carriers and formulation excipients, limited by the requirement that the API component contains the claimed crystal form.
Claim 20: explicit solid dosage formats
- “Wherein the composition is in the form of a tablet, pill, powder or granule.”
If a product is delivered in another form not captured here (for example capsules vs. tablets, or liquid dosage forms), this snippet does not show explicit coverage. The claim language as provided restricts the listed dosage forms.
How many distinct crystal-form “fingerprints” are claimed, and what are their legal attack surfaces?
Short answer: At least four XRPD-basis categories are visible: (i) the single-peak 8.54° form, (ii) the 8.54° + 17.24° variants with multiple tolerance levels, (iii) the 8.54° + 14.02° + 17.24° variants with multiple tolerance levels, and (iv) the full 7-peak fingerprint variants with multiple tolerance levels. The most litigable issue in practice is whether the XRPD criteria correspond to genuinely distinct polymorphs or whether different solids can satisfy the same peak constraints under measurement variability.
Attack surfaces for a defendant (in infringement analysis)
- XRPD mismatch: peak positions outside ± windows.
- Peak absent or not “characteristic”: competitor can argue the peak is not present above noise or not “characteristic” under the method.
- Purity threshold not met: crystallinity or polymorph fraction below claimed percentages.
- Non-inclusion of the claimed crystal form: if the product uses a different polymorph not within claims 1–13.
Attack surfaces for a patentee (in validity/claim construction posture)
- Overbreadth of single-peak claims: a one-peak requirement can be attacked for lack of distinctiveness if other forms share that peak region.
- Ambiguity in “characteristic”: how the patent defines characteristic peaks and which instrument conditions apply.
- Measurement reproducibility: whether tolerance bands account for typical XRPD variability.
(These are standard analytical pressure points for XRPD-defined crystal patents, but the exact success depends on the specification and prosecution history not provided in your prompt.)
What generic/biosimilar entry risks exist for products using different polymorphs or manufacturing processes?
Short answer: For small-molecule drug products, the primary risk driver is whether an ANDA (or other generic) can switch polymorph to avoid XRPD infringement while still meeting performance specs. This patent’s multi-tier XRPD claims raise the likelihood that simply changing crystallization conditions still lands within the same peak fingerprint unless the polymorph identity is materially different.
Design-around scenarios likely considered under this claim set
- Use a different polymorph: target a crystal that does not have the required 8.54° peak within ± tolerance, or lacks one of the additional required peaks for the multi-peak claims.
- Shift the peak slightly: alter polymorph or crystallization microstructure so measured peaks fall outside one or more tolerance windows.
- Reduce the claimed crystal purity fraction: keep the desired polymorph fraction below claim thresholds to avoid claims 14–18.
- Formulate without using the claimed crystal form: swap solid-state form back into the API stage rather than formulation stage, because composition claims are gated by the API solid.
Why the manufacturing barrier matters
The patent attaches to the API’s solid-state properties. Even if the formulation is identical, infringement turns on the polymorph content in the final dosage.
How does this patent’s claim structure compare to typical XRPD crystal patents?
Short answer: US 8,981,103 follows a common crystal patent architecture: XRPD-defined peak fingerprints with tolerance bands, plus purity and formulation follow-ons. The presence of both low-peak-count claims (single peak) and high-peak-count claims (multi-peak fingerprint) expands coverage and increases the chance that at least one claim maps to a competitor’s product characterization.
Coverage layering
- Broad XRPD presence (claim 1)
- Intermediate fingerprint steps (claims 4–9)
- Full fingerprint (claims 10–12)
- Purity thresholds (claims 14–18)
- Composition protection (claims 19–20)
Key Takeaways
- US 8,981,103 protects a specific molecular entity’s crystal forms by XRPD peak position constraints centered on 2θ ~8.54°, with dependent claims adding 14.02° and 17.24° and broader embodiments requiring seven peak fingerprints.
- Claim 1 is the broad XRPD hook (single peak at 8.54 ± 0.2°), while claims 10–12 provide narrower but stronger fingerprint protection via seven peaks with tolerance bands down to ±0.06°.
- Claims 14–18 add a second infringement gate: the claimed crystal must meet crystal purity thresholds from ≥70% to ≥98%.
- Claims 19–20 extend protection to pharmaceutical compositions containing the claimed crystal form, expressly covering tablet, pill, powder, and granule dosage formats.
- For design-around, the key levers are XRPD peak matching within tolerances, polymorph selection, and crystal purity fraction in the API.
FAQs
1) Can a competitor infringe US 8,981,103 by matching only the 8.54° XRPD peak?
Yes, in principle, if their crystal matches the claim 1 requirement of a characteristic diffraction peak at 8.54 ± tolerance as recited. However, other dependent claims impose additional peak requirements.
2) What is the practical difference between the ±0.2°, ±0.1°, and ±0.06° XRPD tolerances?
They define how far the measured peak can shift in 2θ while still meeting the claim. Smaller tolerances make infringement harder for solids where peaks drift due to manufacturing variability or measurement conditions.
3) Do the purity claims (14–18) require the same XRPD peak pattern?
The snippet indicates purity claims depend on the “crystal form of any one of claims 1 and 2 to 13,” so purity thresholds apply to the already XRPD-defined crystal forms in those earlier claims.
4) Are composition claims (19–20) limited to tablet/pill/powder/granule?
Claim 19 covers any pharmaceutical composition with a pharmaceutically acceptable carrier, while claim 20 explicitly narrows to tablet, pill, powder or granule.
5) What is the risk of relying on a different crystallization process?
If the resulting polymorph still produces the required XRPD peaks within the recited tolerances, the product can still fall within the claimed crystal-form boundaries, and purity thresholds can further constrain mixed-solid strategies.
References
- US Patent 8,981,103.
